BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16990113)

  • 1. Immunotoxins in the treatment of refractory hairy cell leukemia.
    Kreitman RJ; Pastan I
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoconjugates in the management of hairy cell leukemia.
    Kreitman RJ; Pastan I
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
    Du X; Ho M; Pastan I
    J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
    Kreitman RJ; Wilson WH; Robbins D; Margulies I; Stetler-Stevenson M; Waldmann TA; Pastan I
    Blood; 1999 Nov; 94(10):3340-8. PubMed ID: 10552943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
    Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
    Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunobiological treatments of hairy-cell leukaemia.
    Kreitman RJ; Pastan I
    Best Pract Res Clin Haematol; 2003 Mar; 16(1):117-33. PubMed ID: 12670470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
    Alderson RF; Kreitman RJ; Chen T; Yeung P; Herbst R; Fox JA; Pastan I
    Clin Cancer Res; 2009 Feb; 15(3):832-9. PubMed ID: 19188153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
    Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
    J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
    Kreitman RJ
    BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
    Kreitman RJ; Pastan I
    Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approach to the patient after relapse of hairy cell leukemia.
    Kreitman RJ; Fitzgerald DJ; Pastan I
    Leuk Lymphoma; 2009 Oct; 50 Suppl 1(Suppl 1):32-7. PubMed ID: 19814696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant single-chain immunotoxins against T and B cell leukemias.
    Kreitman RJ; Pastan I
    Leuk Lymphoma; 1994 Mar; 13(1-2):1-10. PubMed ID: 8025511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
    Benhar I; Pastan I
    Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.
    Guo R; Cao L; Guo W; Liu H; Xu H; Fang Q; Hong Z
    Biochem Biophys Res Commun; 2016 Jun; 475(1):93-9. PubMed ID: 27178207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
    Kreitman RJ; Arons E; Stetler-Stevenson M; Fitzgerald DJ; Wilson WH; Pastan I
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):82-6. PubMed ID: 21599609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotoxins for targeted cancer therapy.
    Kreitman RJ
    AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the
    Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
    Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta.
    Nagai T; Tanaka M; Tsuneyoshi Y; Xu B; Michie SA; Hasui K; Hirano H; Arita K; Matsuyama T
    Cancer Immunol Immunother; 2009 Oct; 58(10):1577-86. PubMed ID: 19238383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoconjugates and new molecular targets in hairy cell leukemia.
    Kreitman RJ
    Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
    Kellner C; Bleeker WK; Lammerts van Bueren JJ; Staudinger M; Klausz K; Derer S; Glorius P; Muskulus A; de Goeij BE; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Aug; 371(1-2):122-33. PubMed ID: 21756911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.